Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers (GUB-BCR-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03413982
Recruitment Status : Recruiting
First Posted : January 29, 2018
Last Update Posted : February 28, 2019
Sponsor:
Information provided by (Responsible Party):
University of Kansas Medical Center

Brief Summary:
The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of patients with bladder cancer, how bladder cancer tissues are related to tumor development, recurrence and survival.

Condition or disease Intervention/treatment
Bladder Cancer Other: Registry

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 24 Months
Official Title: Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
Actual Study Start Date : November 2, 2017
Estimated Primary Completion Date : January 1, 2025
Estimated Study Completion Date : January 1, 2035

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer
Drug Information available for: Coal Tar

Group/Cohort Intervention/treatment
BC Patients
Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
Other: Registry
Patient registry




Primary Outcome Measures :
  1. Blood, urine and tissue characteristics of bladder cancer patients [ Time Frame: 24 months ]
    Samples will be collected over a 24 month period for patients to build a biorepository for future research on how they are related to tumor development, recurrence and survival.


Biospecimen Retention:   Samples Without DNA
Blood, urine, and tissue are being collected.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are receiving care from KUMC clinics will be considered for this registry.
Criteria

Inclusion Criteria:

  • Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate
  • Patients can participate in any additional research studies during the patients' participation within this protocol.

Exclusion Criteria:

  • Patients who do not have presumed bladder cancer will not be eligible

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413982


Contacts
Layout table for location contacts
Contact: Katie Glavin 913-588-8721 kglavin@kumc.edu

Locations
Layout table for location information
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
University of Kansas Medical Center
Investigators
Layout table for investigator information
Principal Investigator: John Taylor, MD University of Kansas Medical Center

Additional Information:

Layout table for additonal information
Responsible Party: University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT03413982     History of Changes
Other Study ID Numbers: STUDY00141546
First Posted: January 29, 2018    Key Record Dates
Last Update Posted: February 28, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Coal Tar
Keratolytic Agents
Dermatologic Agents